Magnetic resonance imaging (MRI) examinations with intravenous (IV) contrast are performed worldwide in routine daily practice. In order to detect and enumerate even rare adverse events (AE) and serious adverse events (SAE), and to relate them with patients’ baseline characteristics and diagnostic effectiveness, high quantity sample size is necessary.
Purpose
To assess safety, diagnostic effectiveness, and baseline characteristics of patients undergoing IV gadoteric acid (Dotarem®) MRI in routine practice.
Material and Methods
Data from two observational post-marketing surveillance (PMS) databases compiled by 139 and 52 German centers in 2004–2011 and 2011–2013, respectively, were pooled, yielding data on a total of 148,489 patients examined over a 10-year period. Radiologists used a standardized questionnaire to report data including patient demographics, characteristics of MR examinations, and results in terms of diagnosis and patient safety.
Results
Overall, 712 AEs were reported in 467 (0.3%) patients, mainly nausea (n = 224, 0.2%), vomiting (n = 29, <0.1%), urticaria (n = 20, <0.1%), and feeling hot (n = 13, <0.1%). AEs were considered related to gadoteric acid in 362 (0.2%) patients. Higher frequencies of AEs were observed among patients with a previous reaction to a contrast agent (2.0%), liver dysfunction (0.7%), bronchial asthma (0.7%), and a history of allergies (0.6%). There were 49 SAEs in 18 (<0.1%) patients, including two children. No fatal SAE was reported. Examinations were diagnostic in 99.8% of all patients, and image quality was excellent or good in 97.7% of the patients.
Conclusion
Gadoteric acid is a safe peri-examinational and effective contrast agent for MRI in routine practice.
RussellEJGeremiaGKJohnsonCE, et al.
Multiple cerebral metastases: Detectability with gd-dtpa-enhanced MR imaging.Radiology1987;
165:609–617.
2.
MarchalGDemaerelPDecropE, et al.
Gadolinium-DOTA enhanced fast imaging of liver tumors at 1.5 T.J Comput Assist Tomogr1990;
14:217–222.
3.
Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: Characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994;190:417–423.
4.
RuehmSGHanyTFPfammatterT, et al.
Pelvic and lower extremity arterial imaging: Diagnostic performance of three-dimensional contrast-enhanced MR angiography.AJR Am J Roentgenol2000;
174:1127–1135.
5.
Seithe T, Braun J, Wolf M, et al. Diagnostic efficacy and safety of gadoteric acid MR mammography in 1537 patients. Eur J Radiol 2016;85:2281–2287.
6.
ThomsenHSMorcosSKAlménT, et al.
Nephrogenic systemic fibrosis and gadolinium-based contrast media: Updated ESUR contrast medium safety committee guidelines.Eur Radiol2013;
23:307–318.
7.
HerbornCUHonoldEWolfM, et al.
Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (gd-dota).Invest Radiol2007;
42:58–62.
8.
HerbornCUJäger-BoothILodemannKP, et al. [
Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (multihance)].Rofo2009;
181:652–657.
9.
KnoppMVBalzerTEsserM, et al.
Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.Invest Radiol2006;
41:491–499.
10.
Law on the Marketing of Medicinal Products (Medicines Act-AMG) Medicines Act, Germany (Arzneimittelgesetz in der Fassung der Bekanntmachung vom 12. Dezember 2005 (BGBl. I S. 3394), das zuletzt durch Artikel 1 des Gesetzes vom 18. Juli 2017 (BGBl. I S. 2757) geändert worden ist, Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz – AMG)). AMG, 2019. Available at: http://www.gesetze-im-internet.de/amg_1976/ (accessed 20 January 2019).
11.
World Health Organization. Obesity: Preventing and managing the global epidemic, report of a WHO consultation. WHO Technical Report Series 253.
Geneva:
WHO, 2000.
Maurer M, Heine O, Wolf M, et al. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: Results in more than 84,000 patients. Eur J Radiol 2012;81:885–890.
14.
SungJSMalakSFBajajP, et al.
Screening breast MR imaging in women with a history of lobular carcinoma in situ.Radiology2011;
261:414–420.
15.
JungJWKangHRKimMH, et al.
Immediate hypersensitivity reaction to gadolinium-based MR contrast media.Radiology2012;
264:414–422.
16.
BalassyCRobertsDMillerSF.Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: Overview of clinical trials and post-marketing studies.Pediatr Radiol2015;
45:1831–1841.
17.
YoungLKMatthewSZHoustonJG.Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (dotarem®) examinations, including 3,209 performed on renally insufficient individuals.Eur Radiol2019;
29:1922–1930.
18.
de KervilerEMaravillaKMederJF, et al.
Adverse reactions to gadoterate meglumine: Review of over 25 years of clinical use and more than 50 million doses.Invest Radiol2016;
51:544–551.
19.
KandaTIshiiKKawaguchiH, et al.
High signal intensity in the dentate nucleus and globus pallidus on unenhanced t1-weighted MR images: Relationship with increasing cumulative dose of a gadolinium-based contrast material.Radiology2014;
270:834–841.
20.
KandaTOsawaMObaH, et al.
High signal intensity in dentate nucleus on unenhanced t1-weighted MR images: Association with linear versus macrocyclic gadolinium chelate administration.Radiology2015;
275:803–809.
21.
KandaTFukusatoTMatsudaM, et al.
Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: Evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy.Radiology2015;
276:228–232.
22.
McDonaldRJMcDonaldJSKallmesDF, et al.
Intracranial gadolinium deposition after contrast-enhanced MR imaging.Radiology2015;
275:772–782.
23.
BarbieriSSchroederCFroehlichJM, et al.
High signal intensity in dentate nucleus and globus pallidus on unenhanced t1-weighted MR images in three patients with impaired renal function and vascular calcification.Contrast Media Mol Imaging2016;
11:245–250.
24.
RadbruchAWeberlingLDKieslichPJ, et al.
Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent.Radiology2015;
275:783–791.
25.
RadbruchAWeberlingLDKieslichPJ, et al.
High-Signal intensity in the dentate nucleus and globus pallidus on unenhanced t1-weighted images: Evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol.Invest Radiol2015;
50:805–810.
26.
RadbruchA.Are some agents less likely to deposit gadolinium in the brain?Magn Reson Imaging2016;
34:1351–1354.
27.
WeberlingLDKieslichPJKickingerederP, et al.
Increased signal intensity in the dentate nucleus on unenhanced t1-weighted images after gadobenate dimeglumine administration.Invest Radiol2015;
50:743–748.
28.
RadbruchAWeberlingLDKieslichPJ, et al.
Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and macrocyclic gadolinium-based contrast agents.Invest Radiol2016;
51:683–690.
29.
RadbruchARobertsDRClementO, et al.
Chelated or dechelated gadolinium deposition.Lancet Neurol2017;
16:955.
30.
RadbruchA.Gadolinium deposition in the brain: We need to differentiate between chelated and dechelated gadolinium.Radiology2018;
288:434–435.
31.
FrenzelTApteCJostG, et al.
Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: Comparative study in rats.Invest Radiol2017;
52:396–404.
32.
RobertPViolasXGrandS, et al.
Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats.Invest Radiol2016;
51:73–82.
33.
JostGFrenzelTLohrkeJ, et al.
Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: A potential pathway of entry into the brain tissue.Eur Radiol2017;
27:2877–2885.
34.
GulaniVCalamanteFShellockFG, et al.
International Society for Magnetic Resonance in Medicine - Gadolinium deposition in the brain: Summary of evidence and recommendations.Lancet Neurol2017;
16:564–570.
35.
ZhengLYangJLiuQ, et al.
Lanthanum chloride impairs spatial learning and memory and downregulates nf-κb signalling pathway in rats.Arch Toxicol2013;
87:2105–2117.
36.
ZarrosAByrneAMBoomkampSD, et al.
Lanthanum-induced neurotoxicity: Solving the riddle of its involvement in cognitive impairment?Arch Toxicol2013;
87:2031–2035.
37.
LiuHYangJLiuQ, et al.
Lanthanum chloride impairs spatial memory through ERK/MSK1 signaling pathway of hippocampus in rats.Neurochem Res2014;
39:2479–2491.
38.
ZhangLYangJJinC, et al.
The effect of nuclear factor erythroid 2-related factor/antioxidant response element signalling pathway in the lanthanum chloride-induced impairment of learning and memory in rats.J Neurochem2017;
140:463–475.
39.
JinCGaoLLiY, et al.
Lanthanum damages learning and memory and suppresses astrocyte-neuron lactate shuttle in rat hippocampus.Exp Brain Res2017;
235:3817–3832.
40.
HuXYangJSunY, et al.
Lanthanum chloride impairs memory in rats by disturbing the glutamate-glutamine cycle and over-activating NMDA receptors.Food Chem Toxicol2018;
113:1–13.
41.
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. Page Last Updated: 05/16/2018. FDA, 2019. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm (accessed 20 January 2019).
42.
SoyerPDohanAPatkarD, et al.
Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.J Magn Reson Imaging2017;
45:988–997.
43.
OudkerkMSijensPEVan BeekEJ, et al.
Safety and efficacy of dotarem (gd-dota) versus magnevist (gd-dtpa) in magnetic resonance imaging of the central nervous system.Invest Radiol1995;
30:75–78.
